【摘要】 目的:探讨依达拉奉联合神经节苷脂治疗重症颅脑损伤对患者GFAP、S100β、HO-1、MMP-9水平的影响。方法:选取我院2019年1月至2020年2月收治的150例重症颅脑损伤患者为观察对象,根据随机数表法将患者分为对照组(n=75,采用神经节苷脂治疗)与联合组(n=75,采用依达拉奉联合神经节苷脂治疗)。比较两组的临床疗效及治疗前后颅脑神经损伤程度[脊髓神经胶质纤维酸性蛋白(GFAP)、星形胶质源性蛋白(S100β)、血红素氧合酶(HO-1)、基质金属蛋白酶-9(MMP-9)]、氧化应激指标[丙二醛(MDA)、髓过氧化物酶(MPO)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)]。结果:联合组的治疗总有效率(96.00%)显著高于对照组(86.67%)(P < 0.05);联合组治疗后GFAP、S100β、HO-1、MMP-9、MDA、MPO水平均低于对照组,而SOD、GSH-Px水平均高于对照组(P < 0.05)。结论:依达拉奉联合神经节苷脂治疗重症颅脑损伤可有效抑制患者机体氧化应激反应,修复患者神经功能,临床疗效显著。更多还原

【Abstract】 Objective:To investigate the effect of edaravone combined with ganglioside on the levels of GFAP,S100 β,HO-1 and MMP-9 in patients with severe brain injury.Methods:150 patients with severe craniocerebral injury admitted to our hospital from January 2019 to February 2020 were selected as the observation objects.According to the random number table,the patients were divided into control group (n=75,treated with ganglioside) and combined group (n=75,treated with edaravone and ganglioside).The clinical effect and the degree of brain injury before and after treatment were compared between the two groups (GFAP,S100 β,HO-1,MMP-9),oxidative stress index[MDA,MPO,SOD,GSH-Px].Results:The total effective rate of the combined group (96.00%) was significantly higher than that of the control group (86.67%) (P < 0.05);the levels of GFAP,S100 β,HO-1,MMP-9,MDA and MPO in the combined group were lower than those in the control group,while the levels of SOD and GSH PX in the combined group were higher than those in the control group (P < 0.05).Conclusion:Edaravone combined with ganglioside in the treatment of severe craniocerebral injury can effectively inhibit the oxidative stress response of patients,repair the nerve function of patients,and has a significant clinical effect.更多还原